Controversy about pharmacological modulation of Nrf2 for cancer therapy

Redox Biology

Volumn 12, Issue , 2017, Pages 727-732

  Milkovic, Lidija ^a   Zarkovic, Neven ^a   Saso, Luciano ^b  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

4 hydroxynonenal; Cancer; Cancer therapy; Growth regulation; Nrf2; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; ANTIOXIDANT; I KAPPA B KINASE BETA; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MALABARICONE A; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; RTA 405; SAXAGLIPTIN; SITAGLIPTIN; SULFORAPHANE; THYMIDINE KINASE; TRANSCRIPTION FACTOR NRF2; TRITERPENOID; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN;

ANTIOXIDANT ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER THERAPY; CARCINOGENESIS; CELLULAR STRESS RESPONSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; LEUKEMIA; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SOLID TUMOR; SUICIDE GENE THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HUMAN; METABOLISM; NEOPLASM; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-E2-RELATED FACTOR 2; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 85017361128     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.04.013     Document Type: Review

References (60)

1. [1] Stewart, B.W., CP, W., (eds.) World Cancer Report 2014, International Agency for Research on Cancer, 2014, WHO, Lyon, France.
2. [2] D. Hanahan, R.A. Weinberg, Chapter 2: Hallmarks of Cancer: An Organizing Principle for Cancer Medicine, in: pp. 1–51, 2011.
3. [3] Soto, A.M., Sonnenschein, C., The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 33 (2011), 332–340, 10.1002/bies.201100025.
4. [4] Sonnenschein, C., Soto, A.M., The aging of the 2000 and 2011 Hallmarks of Cancer reviews: a critique. J. Biosci. 38 (2013), 651–663 〈http://www.ncbi.nlm.nih.gov/pubmed/23938395〉.
5. [5] Sonnenschein, C., Soto, A.M., Rangarajan, A., Kulkarni, P., Competing views on cancer. J. Biosci. 39 (2014), 281–302 〈http://www.ncbi.nlm.nih.gov/pubmed/24736160〉.
6. [6] Baker, S.G., A cancer theory kerfuffle can lead to new lines of research. J. Natl. Cancer Inst. 107 (2015), 1–8, 10.1093/jnci/dju405.
7. [7] Sonnenschein, C., Soto, A.M., Carcinogenesis explained within the context of a theory of organisms. Prog. Biophys. Mol. Biol. 122 (2016), 70–76, 10.1016/j.pbiomolbio.2016.07.004.
8. [8] Milkovic, L., Siems, W., Siems, R., Zarkovic, N., Oxidative stress and antioxidants in carcinogenesis and integrative therapy of cancer. Curr. Pharm. Des. 20 (2014), 6529–6542 〈http://www.ncbi.nlm.nih.gov/pubmed/25341930〉.
9. [9] Panieri, E., Santoro, M.M., ROS homeostasis and metabolism: a dangerous liaison in cancer cells. Cell Death Dis., 7, 2016, e2253, 10.1038/cddis.2016.105.
10. [10] Sever, R., Brugge, J.S., Signal transduction in cancer. Cold Spring Harb. Perspect. Med. 5 (2015), 1–2, 10.1101/cshperspect.a006098.
11. [11] Acharya, A., Das, I., Chandhok, D., Saha, T., Redox regulation in cancer: a double-edged sword with therapeutic potential. Oxid. Med. Cell. Longev. 3 (2010), 23–34, 10.4161/oxim.3.1.10095.
12. [12] Jaramillo, M.C., Zhang, D.D., The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 27 (2013), 2179–2191, 10.1101/gad.225680.113.
13. [13] Taguchi, K., Motohashi, H., Yamamoto, M., Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16 (2011), 123–140, 10.1111/j.1365-2443.2010.01473.x.
14. [14] De Luca, C., Kharaeva, Z., Korkina, L., Is there a role for antioxidants in the prevention of infection-associated carcinogenesis and in the treatment of infection-driven tumors?. Curr. Top. Med. Chem. 15 (2015), 120–135 〈http://www.benthamdirect.org/pages/all_b_bypublication.php%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed13&NEWS=N&AN=2015893760%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/25496269〉.
15. [15] Klaunig, J.E., Kamendulis, L.M., Hocevar, B.A., Oxidative stress and oxidative damage in carcinogenesis. Toxicol. Pathol. 38 (2010), 96–109, 10.1177/0192623309356453.
16. [16] Liou, G.-Y., Storz, P., Reactive oxygen species in cancer. Free Radic. Res. 44 (2010), 479–496, 10.3109/10715761003667554.
17. [17] Harris, I.S., Treloar, A.E., Inoue, S., Sasaki, M., Gorrini, C., Lee, K.C., Yung, K.Y., Brenner, D., Knobbe-Thomsen, C.B., Cox, M.A., Elia, A., Berger, T., Cescon, D.W., Adeoye, A., Brüstle, A., Molyneux, S.D., Mason, J.M., Li, W.Y., Yamamoto, K., Wakeham, A., Berman, H.K., Khokha, R., Done, S.J., Kavanagh, T.J., Lam, C., Mak, T.W., Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27 (2015), 211–222, 10.1016/j.ccell.2014.11.019.
18. [18] Schumacker, P., Reactive oxygen species in cancer: a dance with the devil. Cancer Cell. 27 (2015), 156–157, 10.1016/j.ccell.2015.01.007.
19. [19] Guéraud, F., Atalay, M., Bresgen, N., Cipak, A., Eckl, P.M., Huc, L., Jouanin, I., Siems, W., Uchida, K., Chemistry and biochemistry of lipid peroxidation products. Free Radic. Res. 44 (2010), 1098–1124, 10.3109/10715762.2010.498477.
20. [20] Esterbauer, H., Schaur, R.J., Zollner, H., Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991), 81–128 〈http://www.ncbi.nlm.nih.gov/pubmed/1937131〉.
21. [21] Milkovic, L., Cipak Gasparovic, A., Zarkovic, N., Overview on major lipid peroxidation bioactive factor 4-hydroxynonenal as pluripotent growth-regulating factor. Free Radic. Res. 49 (2015), 850–860, 10.3109/10715762.2014.999056.
22. [22] Zarkovic, N., 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Asp. Med. 24 (2003), 281–291 〈http://www.ncbi.nlm.nih.gov/pubmed/12893006〉.
23. [23] Levonen, A.-L., Landar, A., Ramachandran, A., Ceaser, E.K., Dickinson, D.A., Zanoni, G., Morrow, J.D., Darley-Usmar, V.M., Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem. J. 378 (2004), 373–382, 10.1042/BJ20031049.
24. [24] Numazawa, S., Ishikawa, M., Yoshida, A., Tanaka, S., Yoshida, T., Atypical protein kinase C mediates activation of NF-E2-related factor 2 in response to oxidative stress. Am. J. Physiol. Cell Physiol. 285 (2003), C334–C342, 10.1152/ajpcell.00043.2003.
25. [25] Huang, Y., Li, W., Kong, A.-N.T., Anti-oxidative stress regulator NF-E2-related factor 2 mediates the adaptive induction of antioxidant and detoxifying enzymes by lipid peroxidation metabolite 4-hydroxynonenal. Cell Biosci., 2, 2012, 40, 10.1186/2045-3701-2-40.
26. [26] Łuczaj, W., Gęgotek, A., Skrzydlewska, E., Antioxidants and HNE in redox homeostasis. Free Radic. Biol. Med., 2016, 10.1016/j.freeradbiomed.2016.11.033.
27. [27] Suzuki, T., Shibata, T., Takaya, K., Shiraishi, K., Kohno, T., Kunitoh, H., Tsuta, K., Furuta, K., Goto, K., Hosoda, F., Sakamoto, H., Motohashi, H., Yamamoto, M., Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels. Mol. Cell. Biol. 33 (2013), 2402–2412, 10.1128/MCB.00065-13.
28. [28] Geismann, C., Arlt, A., Sebens, S., Schäfer, H., Cytoprotection “gone astray”: Nrf2 and its role in cancer. Onco Targets Ther. 7 (2014), 1497–1518, 10.2147/OTT.S36624.
29. [29] Menegon, S., Columbano, A., Giordano, S., The dual roles of NRF2 in cancer. Trends Mol. Med. 22 (2016), 578–593, 10.1016/j.molmed.2016.05.002.
30. [30] Kansanen, E., Kuosmanen, S.M., Leinonen, H., Levonenn, A.L., Levonen, A., The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol. 1 (2013), 45–49, 10.1016/j.redox.2012.10.001.
31. [31] Kensler, T.W., Wakabayashi, N., Nrf2: friend or foe for chemoprevention?. Carcinogenesis 31 (2010), 90–99, 10.1093/carcin/bgp231.
32. [32] Kim, J., Keum, Y., NRF2, a key regulator of antioxidants with two faces towards cancer. Oxid. Med. Cell. Longev., 2016, 2016, 2746457, 10.1155/2016/2746457.
33. [33] Lau, A., Villeneuve, N.F., Sun, Z., Wong, P.K., Zhang, D.D., Dual roles of Nrf2 in cancer. Pharmacol. Res. 58 (2008), 262–270, 10.1016/j.phrs.2008.09.003.
34. [34] Sporn, M.B., Liby, K.T., NRF2 and cancer: the good, the bad and the importance of context. Nat. Publ. Gr. 12 (2012), 564–571, 10.1038/nrc3278.
35. [35] Chio, I.I.C., Jafarnejad, S.M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., Wright, K., Filippini, D., Lee, E.J., Silva, B. Da, Schoepfer, C., Wilkinson, J.E., Buscaglia, J.M., DeNicola, G.M., Tiriac, H., Hammell, M., Crawford, H.C., Schmidt, E.E., Thompson, C.B., Pappin, D.J., Sonenberg, N., Tuveson, D.A., NRF2 promotes tumor maintenance by modulating mRNA translation in pancreatic cancer. Cell 166 (2016), 963–976, 10.1016/j.cell.2016.06.056.
36. [36] Abdul-Aziz, A., MacEwan, D.J., Bowles, K.M., Rushworth, S.A., Oxidative stress responses and NRF2 in human leukaemia. Oxid. Med. Cell. Longev. 2015 (2015), 1–7, 10.1155/2015/454659.
37. [37] Gęgotek, A., Nikliński, J., Žarković, N., Žarković, K., Waeg, G., Łuczaj, W., Charkiewicz, R., Skrzydlewska, E., Lipid mediators involved in the oxidative stress and antioxidant defence of human lung cancer cells. Redox Biol. 9 (2016), 210–219, 10.1016/j.redox.2016.08.010.
38. [38] Pettazzoni, P., Ciamporcero, E., Medana, C., Pizzimenti, S., Dal Bello, F., Minero, V.G., Toaldo, C., Minelli, R., Uchida, K., Dianzani, M.U., Pili, R., Barrera, G., Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free Radic. Biol. Med. 51 (2011), 1610–1618, 10.1016/j.freeradbiomed.2011.07.009.
39. [39] Syu, J., Chi, J., Kung, H., Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia. Oncotarget 7 (2016), 14659–14672, 10.18632/oncotarget.7406.
40. [40] Frijhoff, J., Winyard, P.G., Zarkovic, N., Davies, S.S., Stocker, R., Cheng, D., Knight, A.R., Taylor, E.L., Oettrich, J., Ruskovska, T., Gasparovic, A.C., Cuadrado, A., Weber, D., Poulsen, H.E., Grune, T., Schmidt, H.H.H.W., Ghezzi, P., Clinical relevance of biomarkers of oxidative stress. Antioxid. Redox Signal. 23 (2015), 1144–1170, 10.1089/ars.2015.6317.
41. [41] Shelton, P., Jaiswal, A.K., The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?. FASEB J. 27 (2013), 414–423, 10.1096/fj.12-217257.
42. [42] Wondrak, G.T., Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid. Redox Signal. 11 (2009), 3013–3069, 10.1089/ARS.2009.2541.
43. [43] Yasueda, A., Urushima, H., Ito, T., Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: a systematic review. Integr. Cancer Ther., 2015, 10.1177/1534735415610427.
44. [44] Vatsyayan, R., Lelsani, P.C.R., Awasthi, S., Singhal, S.S., RLIP76: a versatile transporter and an emerging target for cancer therapy. Biochem. Pharmacol. 79 (2010), 1699–1705, 10.1016/j.bcp.2010.01.016.
45. [45] Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., Sarkar, S., Drug resistance in cancer: an overview. Cancers (Basel) 6 (2014), 1769–1792, 10.3390/cancers6031769.
46. [46] Cort, A., Ozben, T., Saso, L., De Luca, C., Korkina, L., Redox control of multidrug resistance and its possible modulation by antioxidants. Oxid. Med. Cell. Longev., 2016, 2016, 10.1155/2016/4251912.
47. [47] Magesh, S., Chen, Y., Hu, L., Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 32 (2012), 687–726, 10.1002/med.21257.
48. [48] Korkina, L.G., De Luca, C., Kostyuk, V.A., Pastore, S., Plant polyphenols and tumors: from mechanisms to therapies, prevention, and protection against toxicity of anti-cancer treatments. Curr. Med. Chem. 16 (2009), 3943–3965, 10.2174/092986709789352312.
49. [49] Ullah, M., Sulforaphane (SFN): an isothiocyanate in a cancer chemoprevention paradigm. Medicines 2 (2015), 141–156, 10.3390/medicines2030141.
50. [50] Kensler, T.W., Chen, J.G., Egner, P.A., Fahey, J.W., Jacobson, L.P., Stephenson, K.K., Ye, L., Coady, J.L., Wang, J.B., Wu, Y., Sun, Y., Zhang, Q.N., Zhang, B.C., Zhu, Y.R., Qian, G.S., Carmella, S.G., Hecht, S.S., Benning, L., Gange, S.J., Groopman, J.D., Talalay, P., Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo Township, Qidong, People's Republic of China. Cancer Epidemiol. Biomark. Prev. 14 (2005), 2605–2613, 10.1158/1055-9965.EPI-05-0368.
51. [51] Sharma, R., Sharma, A., Chaudhary, P., Sahu, M., Jaiswal, S., Awasthi, S., Awasthi, Y.C., Role of 4-hydroxynonenal in chemopreventive activities of sulforaphane. Free Radic. Biol. Med. 52 (2012), 2177–2185, 10.1016/j.freeradbiomed.2012.04.012.
52. [52] Probst, B.L., McCauley, L., Trevino, I., Wigley, W.C., Ferguson, D.A., Cancer cell growth is differentially affected by constitutive activation of NRF2 by KEAP1 deletion and pharmacological activation of NRF2 by the synthetic triterpenoid, RTA 405. PLoS One, 10, 2015, e0135257, 10.1371/journal.pone.0135257.
53. [53] Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., Li, W., Tang, Z., Tong, Q., Wang, X., Fang, F., de la Vega, M.R., Ouyang, Q., Zhang, D.D., Yu, S., Zheng, H., NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci. Transl. Med., 8, 2016, 334ra51, 10.1126/scitranslmed.aad6095.
54. [54] Wang, X.J., Sun, Z., Villeneuve, N.F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G.T., Wong, P.K., Zhang, D.D., Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29 (2008), 1235–1243, 10.1093/carcin/bgn095.
55. [55] Manna, A., De Sarkar, S., De, S., Bauri, A.K., Chattopadhyay, S., Chatterjee, M., The variable chemotherapeutic response of Malabaricone-A in leukemic and solid tumor cell lines depends on the degree of redox imbalance. Phytomedicine 22 (2015), 713–723, 10.1016/j.phymed.2015.05.007.
56. [56] Liu, W., Porter, N.A., Schneider, C., Brash, A.R., Yin, H., Formation of 4-hydroxynonenal from cardiolipin oxidation: intramolecular peroxyl radical addition and decomposition. Free Radic. Biol. Med. 50 (2011), 166–178, 10.1016/j.freeradbiomed.2010.10.709.
57. [57] Zhong, H., Xiao, M., Zarkovic, K., Zhu, M., Sa, R., Lu, J., Tao, Y., Chen, Q., Xia, L., Cheng, S., Waeg, G., Zarkovic, N., Yin, H., Mitochondrial control of apoptosis through modulation of cardiolipin oxidation in hepatocellular carcinoma: a novel link between oxidative stress and cancer. Free Radic. Biol. Med. 102 (2017), 67–76, 10.1016/j.freeradbiomed.2016.10.494.
58. [58] Gao, A., Ke, Z., Wang, J., Yang, J., Chen, S.-Y., Chen, H., Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway. Carcinogenesis 34 (2013), 1806–1814, 10.1093/carcin/bgt108.
59. [59] Broekgaarden, M., Weijer, R., van Gulik, T.M., Hamblin, M.R., Heger, M., Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies. Cancer Metastas-. Rev. 34 (2015), 643–690, 10.1007/s10555-015-9588-7.
60. [60] Leinonen, H.M., Ruotsalainen, A.K., Määttä, A.M., Laitinen, H.M., Kuosmanen, S.M., Kansanen, E., Pikkarainen, J.T., Lappalainen, J.P., Samaranayake, H., Lesch, H.P., Kaikkonen, M.U., Ylä-Herttuala, S., Levonen, A.L., Oxidative stress-regulated lentiviral TK/GCV gene therapy for lung cancer treatment. Cancer Res. 72 (2012), 6227–6235, 10.1158/0008-5472.CAN-12-1166.